Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Phase 4

Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation

NCT06645249 · tracked via the Priya Life Science Spain tracker
Phase
Phase 4
Started
2024-12-10
Last updated
2024-12-02

Condition(s) studied

Atrial Fibrillation (AF)

Investigational drug(s) / intervention(s)

Amiodarone (Antiarrhythmic drug) →

Amiodarone (Antiarrhythmic drug): Comparing 2 regimes of amiodarone pre-electrical cardioversion witn ECG monitoring

Study summary

Phase: IV Population: Sample size= 122 patients; male and female; ≥ 18 y.o.; patients with persistent atrial fibrillation referred for electrical cardioversion; performed in Spain Number of Sites: 4 Study Duration: 15/10/2024 - 15/5/2026 Subject Participation Duration: 2-4 months (depending on the arm) Description of Agent or Intervention: amiodarone

Objectives:

Primary: To compare the efficacy of amiodarone in pre-ECV reversal to sinus rhythm in a one-month impregnation regimen versus a 5-day regimen Secondary: 1) Identify days from initiation of pre-ECV amiodarone to reversion to SR using a mobile device paired to the mobile phone; 2) To compare the joint efficacy in the reversion to SR pre-ECV and in the maintenance of SR at 1 month after ECV of a one-month pre-ECV amiodarone impregnation regimen vs a 5-day regimen

Description of Study Design: Multicenter randomized open clinical trial. 122 Patients with persistent AF (≥7 days duration) electively referred for CVE will be included. Two amiodarone regimens administered pre-CVE will be compared evaluating their cardioverter efficacy. Patients will be randomized to 2 groups:

1. Treatment impregnation with amiodarone starting one month before ECV (600 mg/day 1st week, 400 mg/day 2nd week and 200 mg/day thereafter until ECV).
2. Treatment impregnation with amiodarone 800 mg/day started 5 days before ECV. Estimated Time to Complete Enrollment: 13 months

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients ≥18 years old. 2. Persistent atrial fibrillation (≥ 7 days duration). 3. Referred for elective electrical cardioversion. 4. Signing of the informed consent Exclusion Criteria: 1. Need of urgent electrical cardioversion 2. Mean Heart rate \<50 bpm 3. Planned ablation \< 1 month after ECV. 4. Treatment with anti-arrhythmic drugs (IC, III) the last 7 days previous to inclusion (in the case of amiodarone on the 30 days previous to inclusion) 5. Atrial fibrillation post-cardiac surgery 6. New York Heart Association (NYHA) Class IV heart failure 7. Left ventricular ejection fraction (LVEF) ≤30% 8. History of thyroid disease (hyperthyroidism or hypothyroidism) 9. Known hepatobiliary disease (acute hepatitis, cirrhosis...) or ALT/AST \> 3 x upper limit of normal (ULN) 10. Allergy, intolerance, or known hypersensitivity to study medication 11. Women of childbearing potential unwilling to use contraceptive measures 12. Participation in another clinical trial involving investigational drugs 13. Life expectancy less than 12 months 14. Rheumatic mitral stenosis of any degree or severe mitral or aortic valve dysfunction.

Primary outcome measure(s)

  • Reversal to sinus rhythm pre-electrical cardioversion — From date of enrollment until the date of electrical cardioversion, up to 8 weeks
    Number of patients who revert to sinus rhythm before electrical cardioversion

Trial sites (4)

FacilityCityRegionStatus
Hospital Universitari Germans Trias i Pujol Badalona Spain
Hospital de la Santa Creu i Sant Pau Barcelona Spain
Hospital Universitari de Sant Joan Reus Spain
Hospital Clínico Universitario de Santiago Santiago de Compostela Spain
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06645249 on ClinicalTrials.gov ↗ ← All trials in Spain